Aurobindo Pharma's Unit Inks License Agreement for Pediatric Vaccine

28 Sep 2023 , 12:30 PM

Aurobindo Pharma’s subsidiary, Auro Vaccines Private Ltd, entered a license agreement with Hilleman Laboratories Singapore Pte Ltd. The agreement focuses on developing, manufacturing, and commercializing a pentavalent vaccine for pediatric use.

Auro Vaccines Private Ltd will make milestone payments to Hilleman Laboratories upon achieving specific developmental and clinical study milestones. Hilleman Laboratories will receive royalties upon the successful commercialization of the vaccine candidate as part of the agreement.

Aurobindo Pharma clarifies that Auro Vaccines Private Limited is not a material subsidiary, hence this agreement isn’t categorized as a significant event. The agreement is not expected to have a significant impact on Aurobindo Pharma’s financials or operations at present.

Aurobindo Pharma commits to informing exchanges and stakeholders promptly about any future significant developments affecting the company or its subsidiaries.

For feedback and suggestions, write to us at [e-mail]